Rational considerations about development of live attenuated Yersinia pestis vaccines

Wei Sun, Roy Curtiss

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.

Original languageEnglish (US)
Pages (from-to)878-886
Number of pages9
JournalCurrent Pharmaceutical Biotechnology
Volume14
Issue number10
DOIs
StatePublished - 2013

Keywords

  • Immune response
  • Live attenuated Y. pestis vaccines
  • Plague
  • Yersinia pestis

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Rational considerations about development of live attenuated Yersinia pestis vaccines'. Together they form a unique fingerprint.

  • Cite this